Johnson & Johnson (NYSE:JNJ) Shares Sold by Signet Financial Management LLC

Signet Financial Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% during the 1st quarter, HoldingsChannel.com reports. The firm owned 17,317 shares of the company’s stock after selling 623 shares during the period. Signet Financial Management LLC’s holdings in Johnson & Johnson were worth $2,872,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Tallon Kerry Patrick acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $290,000. Capital & Planning LLC raised its holdings in Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after purchasing an additional 183 shares during the last quarter. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new stake in Johnson & Johnson in the fourth quarter valued at $85,886,000. Finally, Adero Partners LLC increased its position in shares of Johnson & Johnson by 19.0% in the fourth quarter. Adero Partners LLC now owns 13,233 shares of the company’s stock valued at $1,914,000 after buying an additional 2,116 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on JNJ shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James cut their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Up 0.1%

Shares of NYSE JNJ opened at $155.19 on Tuesday. The stock has a market capitalization of $373.40 billion, a PE ratio of 23.34, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a fifty day moving average of $153.59 and a 200-day moving average of $153.67. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.35%. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.